Cstone Pharmaceuticals Co. Ltd. is an investment holding company, which engages in the research and development of complex biopharmaceutical products and sale of pharmaceutical products. The company is headquartered in Suzhou, Jiangsu and currently employs 131 full-time employees. The company went IPO on 2019-02-26. Through its subsidiaries, the Company is primarily engaged in the research and development of biopharmaceutical products, sale of pharmaceutical products and provision of license of its intellectual property (IP) or commercialization license. The Company’s main products include targeted therapies, AYVAKIT (avapritinib) and GAVRETO (pralsetinib). The firm is also involved in the development and commercialization of immuno-oncology. The firm mainly conducts its businesses in the domestic market and overseas markets, such as Central and Eastern Europe and Switzerland.
Follow-Up Questions
CStone Pharmaceuticals 的 CEO 是谁？
Dr. Jianxin Yang 是 CStone Pharmaceuticals 的 Chief Executive Officer，自 2016 加入公司。
CSPHF 股票的价格表现如何？
CSPHF 的当前价格为 $0，在上个交易日 decreased 了 0%。
CStone Pharmaceuticals 的主要业务主题或行业是什么？
CStone Pharmaceuticals 属于 Biotechnology 行业，该板块是 Health Care
